Gastric carcinoma (GC) is the 2nd most common cause of cancer-related death. Despite advances in conventional treatment and surgical interventions, a high percentage of GC patients still have poor survival. Recently, immunotherapy has become a promising approach to treat GC. Here, we present preclinical and clinical studies encouraging the use of vaccination, adoptive T-cell therapy (ACT), and ...

High-risk human papillomavirus types are associated with most of cervical cancer cases. To explore the mechanism by which 16 infections interferes progression and immune evasion acting on T helper 9 cells cytokines. Cervical were obtained from China Center for Type Culture Collection. Cells cultured in Roswell Park Memorial Institute Medium-1640. Through wound healing test transwell analysis, e...

Immunotherapies involving chimeric antigen receptor (CAR) T cells and checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) antagonists, have shown promise in treating cancer. The combined benefits of these medicines are yet not fully understood. In this work, it was discovered that human CAR become hypo-functional due to the expression ligand (PD-L1) on tumor cells, which reduc...

Prolonged survival and durable responses in several late-stage cancers such as melanoma lung cancer have been made possible with the use of immune checkpoint inhibitors targeting programmed cell-death protein 1 (PD-1) or its ligand PD-L1. While it is prudent to focus on unprecedented clinical responses, there are subsets patients that do not respond immunotherapies early then relapse later. Man...